Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193606 | SCV001362553 | uncertain significance | not specified | 2019-07-19 | criteria provided, single submitter | clinical testing | Variant summary: GALT c.1094A>G (p.His365Arg) results in a non-conservative amino acid change located in the Galactose-1-phosphate uridyl transferase, C-terminal domain (IPR005850) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251440 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1094A>G in individuals affected with Galactosemia and no experimental evidence demonstrating its impact on protein function have been reported. No submitters have provided clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Mayo Clinic Laboratories, |
RCV003480982 | SCV004224258 | uncertain significance | not provided | 2023-02-28 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2 |
Natera, |
RCV001833745 | SCV002085260 | uncertain significance | Galactosemia | 2020-06-20 | no assertion criteria provided | clinical testing |